1. Immunology and Inflammation
Download icon

Autoimmunity: Treating type-1 diabetes with an epigenetic drug

  1. Yohko Kitagawa
  2. Naganari Ohkura  Is a corresponding author
  1. Osaka University, Japan
Insight
Cite this article as: eLife 2014;3:e05720 doi: 10.7554/eLife.05720
1 figure

Figures

The effects of I-BET151 on the resolution of insulitis and the prevention of type-1 diabetes.

Progression to type-1 diabetes is characterised by chronic inflammation and a loss of function of islet β cells (shown in pale orange). This reduces the proliferation of these cells and often leads to a form of programmed cell death called apoptosis (bottom left). Fu et al. reveal that I-BET151 works to resolve inflammation of the islet β cells (insulitis) mainly by two mechanisms. Firstly, it encourages macrophages in the pancreas to convert from being pro-inflammatory (which release cytokines that promote inflammation, top left) to being anti-inflammatory type (top right). This inhibits the further recruitment of T cells and dampens inflammation. Secondly, I-BET151 enhances the proliferation of islet β cells and enhances insulin production (bottom right).

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)